5 Comments
 
Most Helpful

Yes, you are right— you would not use a DCF in this case because positive cash flows (the very things you are using to estimate value) are non-existent. I guess you could make a case for running a DCF on a pre-earnings company if you were extremely confident in positive earnings predictions in the years ahead... but that’s definitely a stretch and I’m not sure anyone would give it much weight. Much better to use comps and PTs.

You typically don’t use a DCF for pre-earnings companies (as discussed) or companies that have very volatile earnings that are hard to predict with any level of accuracy.

 

DCF: The issue isn't negative earnings so much as the FCF being unstable. Note that you may have negative earnings with positive cash flows but this still insufficient. Negative earnings implies that company isn't stable yet. Negative earnings aren't sustainable long-term so you know the company is either still in growth stage or distressed/on a downturn. Either way, the company's FCF will be unstable and you cannot use the perpetuity growth method to conclude a DCF valuation until the company has stabilized its growth. 

You'd focus on comps multiples off of stabilized positive values - for TEV, is EBITDA positive? If not, use a sales multiple.

Earnings may be negative but what about FCF? You could try P/FCF. Lots of tech SaaS are earnings negative but FCF positive and you could slap on 20-30x multiple to get an equity valuation.

Array
 

You can still do a DCF with negative earnings, this happens all the time for clinical-stage life sciences companies. You need to push out your time horizon.

 

Autem voluptatibus officiis eaque labore. Qui assumenda aut et nihil. Illum hic voluptatum aperiam quia et molestiae iusto asperiores.

Velit minima iure sequi non numquam quas eligendi. Voluptas voluptas laboriosam cum voluptatibus.

A ab blanditiis dicta velit. Id quas iste et repellat. Reiciendis dolorem ipsum adipisci delectus ad enim occaecati culpa. Et et ullam saepe vitae fugit. Provident ex aut adipisci id earum. Est delectus ullam et neque reiciendis animi enim. Et id repellat nobis voluptatem.

I don't know... Yeah. Almost definitely yes.

Career Advancement Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Morgan Stanley 08 97.8%
  • Goldman Sachs 02 97.3%

Overall Employee Satisfaction

August 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.4%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.4%
  • Goldman Sachs 01 97.8%
  • JPMorgan No 97.3%

Total Avg Compensation

August 2026 Investment Banking

  • Vice President (16) $429
  • Associates (49) $260
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (25) $178
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (75) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
GameTheory's picture
GameTheory
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
DrApeman's picture
DrApeman
98.9
8
dosk17's picture
dosk17
98.9
9
CompBanker's picture
CompBanker
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”